1. France Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Valneva SE

Valneva SE

VALN
Valneva SEUS flagNASDAQ Global Select
5.58
USD
-0.05
- -
496.94MMarket Cap
Valneva SE
VALN
(NASDAQ Global Select)

Recent

price

5.58

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
0.55
0.98
0.32
1.55
1.33
2.15
2.52
2.72
2.81
2.75
2.43
7.13
6.25
2.21
2.33
- -
1.75
Revenue per Share
-0.91
-0.42
-1.4
-1.23
-0.95
-0.57
-1.32
-0.3
0.08
-0.04
-1.42
-1.5
-2.48
-1.46
-0.17
- -
-1.55
Basic EPS, GAAP
-1.03
-1.6
-1.5
-1.23
-0.67
-0.62
0.08
0.23
0.33
-0.12
2.61
-0.33
-4.75
-3.12
-1.15
- -
-0.54
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-2.04
-2.06
-3.41
-2.76
-2.96
-2.79
-4.1
-4.14
-3.84
-3.39
-4.85
-5.97
-7.43
-7.64
-7.41
- -
-7.69
Book Value per Share
3.29
1.93
0.83
0.95
0.69
1.26
1.1
1.14
2.44
2.03
0.93
2.82
3.31
1.48
2.14
- -
0.62
Tangible Book Value per Share
9
10
11
20
28
36
37
39
40
46
45
49
58
69
73
- -
89
Basic Weighted Avg Shares
5
10
3
30
37
78
94
105
113
126
110
348
361
154
170
175
156
Sales/Revenue/Turnover
-173.87
-29.99
-374.88
-72.64
-64.33
-25.48
-45.12
-3.75
5.54
-0.64
-49.96
-17.62
-31.4
-53.42
-45.86
-46.74
-63.56
Operating Margin (%)
3
3
5
9
12
11
11
11
7
9
10
14
21
18
20
22
- -
Depreciation Expense
-8
-4
-15
-24
-26
-21
-49
-11
3
-2
-64
-73
-143
-101
-12
-115
-138
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
2.63
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-164.47
-43.06
-432.56
-79.19
-71.15
-26.31
-52.29
-10.91
2.89
-1.38
-58.37
-21.09
-39.66
-65.99
-7.22
-65.95
-88.3
Profit Margin (%)
34
20
5
35
34
70
52
46
83
88
133
217
147
104
184
129
107
Working Capital
6
5
5
65
66
77
62
54
40
81
96
104
115
162
193
187
188
LT Debt
44
40
26
144
124
144
100
93
143
135
77
171
220
128
181
106
77
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
3.33
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
-7.49
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
62
21
21
LT Borrowings
109
161
164
LT Finance Leases
25
25
24
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
172
173
174
Market Capitalization
800
578
482

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
268
223
201
Cash, Cash Equivalents & STI
143
110
105
Accounts Receivable, Net
20
28
10
Inventories
64
50
51
Total Current Liabilities
150
93
94
Payables & Accruals
49
31
44
ST Debt
62
21
21
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
7.55%
21.49%
-41.43%
Free Cash Flow
-94.05%
272.11%
-31.42%
Net Income, GAAP
420.49%
166.52%
840.57%
Sales/Revenue/Turnover
21.36%
35.04%
3%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
33
38
46
53
170
2025
49
48
29
48
175
2026
31
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.84
- -
- -
- -
-0.17
2025
-0.12
- -
- -
- -
- -
2026
-0.36
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Tryp Therapeutics Inc. (TRYPF)
Oncorus, Inc. (ONCR)
Forma Therapeutics Holdings, Inc. (FMTX)
Ascelia Pharma AB (publ) (ACE.ST)
MEDIPOST Co., Ltd. (078160.KQ)
Synairgen plc (SYGGF)
Business
Valneva SE, a specialty vaccine company, develops, manufactures and commercializes prophylactic vaccines targeting infectious diseases with significant unmet medical needs, including travelers' vaccines and candidates against Lyme disease, chikungunya, Shigella and Zika; its commercial portfolio comprises three proprietary products -- IXCHIQ, a single-shot chikungunya vaccine approved by the US FDA in 2023 and launched in the US in early 2024; IXIARO/JESPECT, an inactivated vaccine for Japanese encephalitis prevention; and DUKORAL, an oral vaccine against cholera and enterotoxigenic E. coli (ETEC) diarrhea -- marketed primarily to travelers, military personnel and individuals in endemic regions through direct sales in the US, Canada, UK and Nordics, and partnerships elsewhere. The company also leverages technologies such as the EB66 cell line and IC31 adjuvant through collaborations with pharmaceutical partners. Founded in 2013 through the merger of Intercell AG and Vivalis SA, Valneva SE maintains headquarters in Saint-Herblain, France, with manufacturing sites in Livingston, Scotland; Solna, Sweden; and Vienna, Austria; and operations across six countries employing over 700 people. Recent developments include a October 2025 debt refinancing agreement with Pharmakon Advisors for up to $500 million in non-dilutive financing, featuring an initial $215 million tranche to retire prior debt, extended maturities to 2030, lower interest rates and access to growth capital for business development; expansion of IXCHIQ access in Asia via partnership with Serum Institute of India; positive final Phase 2 results and ongoing Phase 3 VALOR trial for Lyme disease candidate VLA15 partnered with Pfizer, targeting regulatory submissions in 2026; a positive CHMP opinion for IXCHIQ in Europe; and nine-month 2025 revenues of €127.0 million with confirmed full-year guidance of €165-180 million total revenues. Valneva lists on Nasdaq (VALN) and Euronext Paris (VLA), with Pfizer holding approximately 8.1% equity tied to the Lyme partnership.

Company News

APIChat

  • globenewswire.com

    Valneva to Participate at U.S. and European Investor Conferences in June

  • globenewswire.com

    Valneva annonce sa participation à des conférences investisseurs aux États-Unis et en Europe

  • globenewswire.com

    Valneva to Participate at U.S. and European Investor Conferences in June

  • marketbeat.com

    Valneva Q1 Earnings Call Highlights

  • seekingalpha.com

    Valneva SE (VALN) Q1 2026 Earnings Call Transcript

  • globenewswire.com

    Valneva Reports First Quarter 2026 Financial Results and Provides Corporate Updates

  • prnewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN

  • globenewswire.com

    VALNEVA: Declaration of shares and voting rights - Status as of April 30, 2026 taking into account interim information as at May 5, 2026

  • globenewswire.com

    Valneva to Report First Quarter 2026 Consolidated Financial Results on May 13, 2026

  • prnewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN

  • globenewswire.com

    Valneva Announces the Successful Completion of an €84 million Reserved Offering

  • globenewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN

  • globenewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN

  • globenewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Valneva SE – VALN

  • prnewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN

  • globenewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN

  • prnewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN

  • globenewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN

  • globenewswire.com

    Declaration of shares and voting rights of Valneva SE – March 2026

  • prnewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN